Peptide Cycling and Receptor Desensitization by Peptide Class

Your Receptors Are Getting Tired

A common forum complaint is that a peptide worked for a few weeks and then faded. The usual explanation is timing, not dose: the idea is that months of continuous use let the body adapt.

This is a basic principle of pharmacology called receptor desensitization or downregulation. Think of it like this: if you walk into a room with a strong smell, it's overwhelming at first. After ten minutes, you barely notice it. Your olfactory receptors have adapted to the constant signal. Many hormone receptors, including the ones growth hormone (GH) peptides target, can do something similar. Under constant stimulation, a cell may pull receptors from its surface or make them less responsive to the signal.

If that happens, the downstream effects (the GH pulse and the rise in IGF-1) get weaker even though the dose hasn't changed. That's the main reason people cycle. How much it actually happens in people depends on the receptor, and the human data are thin, so this page takes each class in turn.

The GH Axis: The Classic Case for Cycling

Most cycling discussions are about growth hormone secretagogues. Two classes of peptides dominate this category, and they act on different receptors in the growth hormone pathway:

• Growth Hormone Releasing Hormones (GHRHs): These are analogs like Mod GRF 1-29 (CJC-1295 no DAC) or Tesamorelin. They bind to the GHRH receptor on the pituitary gland, telling it to produce and release GH. Tesamorelin's year-long trials (below) suggest this pathway holds up under daily use.
• Growth Hormone Releasing Peptides (GHRPs): These include peptides like Ipamorelin, GHRP-6, and GHRP-2. They bind to a different receptor, the ghrelin receptor (or GHSR). This binding triggers a GH pulse of its own and also amplifies the pulse from a GHRH. In a 2004 study in older adults, infusing GHRP-2 with GHRH raised GH more than either peptide alone.

The ghrelin receptor is the one usually blamed for tolerance, and there is some human evidence behind that. In a 16-week study, 12 healthy older adults injected hexarelin (another GHRP) twice daily. Their GH response fell by about 30% within the first week and was down about 45% by week 16. The loss was partial, and when hexarelin was given again four weeks after the course ended, the response was back to baseline.

Other human data point the other way. In the same 2004 study, a 30-day continuous subcutaneous infusion of GHRP-2 kept GH secretion pulsatile and raised, although the boost shrank from more than 3-fold on day 1 to about 1.8-fold on days 14 and 30. And in a 2-year trial of MK-677 (ibutamoren, an oral compound that also acts on the ghrelin receptor), 65 adults aged 60-81 took 25 mg daily, and their GH and IGF-1 rose into the young-adult range; the two-year analyses confirmed the one-year results. The compounds and populations differ, but together these suggest the loss is real but partial and reversible. No study has tested whether an on/off schedule prevents it.

Practical Cycling Models for GH Secretagogues

There isn't one single "best" way to cycle, but there are a few models the community has settled on. They come from forums and vendor guides, not trials. The goal for all of them is the same: give the GHSR a break to resensitize.

On forums, 5-on/2-off within a 12-to-16-week run is the pattern described most often. Users also report hexarelin tolerance after roughly four weeks, which fits the trial, where most of the drop came in the first month. Our article on hard cycling versus pulse dosing compares those philosophies.

Do You Need to Cycle Healing Peptides?

This is a common question, and no human study has answered it either way. Peptides like BPC-157 and TB-500 (a 7-amino-acid fragment of the larger protein thymosin beta-4) aren't known to work through a single hormone receptor that gets downregulated, so the GH-axis reasoning doesn't carry over directly.

In rodent studies, BPC-157 has been linked to growth factor signaling, the nitric oxide pathway, and angiogenesis (new blood vessel formation) at the site of injury. Thymosin beta-4 binds actin, a protein central to cell migration and tissue repair; most of that work used the full protein in cells and animals, not the TB-500 fragment. As of October 2026, no controlled human trial of either peptide has published results, and no study has looked for tolerance.

With no known receptor to wear out, users tend to let the injury set the length of a run, stopping when the pain is gone or progress plateaus. Vendor and community guidance for BPC-157 commonly gives 4-12 weeks, but no study has tested any duration. "No need to cycle" is an inference from missing data, not a finding, and the bigger gap is safety: no animal study of BPC-157 has assessed adverse events beyond 6 weeks.

The Tesamorelin Exception

Not all GHRH analogs have the same long-term data. Tesamorelin, a stabilized GHRH analog, is a prescription medicine (Egrifta) approved in the US only to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. In its two Phase 3 trials, patients injected 2 mg daily for 26 weeks, and in the extension phase some continued for a full 52 weeks.

It kept working. In the extension, the drop in visceral adipose tissue (VAT) held at about 18% over 52 weeks of treatment, while patients switched to placebo at week 26 regained it. That suggests the GHRH receptor is more resilient to desensitization than the GHSR, though the trials weren't designed to test it.

As of October 2026, the Egrifta WR label gives a once-daily dose (1.28 mg) with no set course length and no off-days. It notes that long-term cardiovascular safety hasn't been established and asks prescribers to weigh continuing in patients whose visceral fat hasn't dropped. It also advises monitoring IGF-1: in the trials, 47% of patients had IGF-1 above the normal range at 26 weeks. The 5-on/2-off tesamorelin schedules on forums are a community practice, not part of the label, and the label says tesamorelin isn't indicated for weight-loss management.

What We Still Don't Know

The case for cycling rests on sound pharmacology and a small amount of human data, and the gaps differ by class:

• GHRPs (ipamorelin, GHRP-6 and others): one 16-week hexarelin study shows a partial, reversible loss of GH response. No study has compared on/off schedules with continuous use, and the 2-year MK-677 trial found GH and IGF-1 still raised.
• Healing peptides (BPC-157, TB-500): there are no human data on tolerance or on how long a run should last. Cycle lengths come from injury timelines and vendor guidance.
• GHRH analogs (Mod GRF, tesamorelin): tesamorelin's 52-week data show no loss of effect on visceral fat. Whether breaks change anything for Mod GRF hasn't been studied.

Rising IGF-1 and glucose over long runs are covered in our page on long-term effects of peptide use, and dosing frequency in how half-life shapes dosing schedules.